Understand the source comparison
Cerebrolysin Before and After: Dosing Protocol Comparison
Cerebrolysin before and after outcomes depend heavily on protocol design. The table below summarizes findings from peer-reviewed trials, illustrating how dose, duration, and treatment cycles influence measurable results. Single 10-day cycle 10mL IV daily × 10
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin before and after outcomes depend heavily on protocol design. The table below summarizes findings from peer-reviewed trials, illustrating how dose, duration, and treatment cycles influence measurable results.
- Single 10-day cycle
- 10mL IV daily × 10 days
- Ischemic stroke (acute)
- NIHSS improvement at 30 days
- Non-significant (p=0.12)
- Insufficient duration for neuroplastic consolidation. Acute neuroprotection only
- Single 21-day cycle
- 30mL IV daily × 21 days
- Post-stroke rehabilitation
- Barthel Index at 90 days
- Significant (+18 points vs placebo, p=0.03)
- Gold standard for stroke recovery. 90-day endpoint allows time for functional reorganization
- Dual-cycle protocol
- 30mL IV × 10 days, repeated after 4-week washout
- Vascular dementia
- ADAS-Cog at 12 weeks
- Significant (−4.2 points vs placebo, p=0.008)
- Repeated cycles show cumulative effect. Optimal for chronic neurodegenerative conditions
- Extended low-dose
- 5mL IM 3× per week × 12 weeks
- Mild cognitive impairment
- MMSE at 12 weeks
- Modest (+1.4 points, p=0.09)
- Lower doses require longer exposure. Effect size limited in mild impairment
- High-dose acute
- 50mL IV daily × 10 days
- Severe TBI (Glasgow <8)
- Glasgow Outcome Scale at 6 months
- Significant (favorable outcome 62% vs 41%, p=0.02)
- High dose justified in severe injury. Adverse event rate acceptable given population